Baxter International Inc. (BAX)
Chart Events
Performance Outlook
| Previous Close | 81.15 |
| Open | 80.61 |
| Bid | 80.06 x 1100 |
| Ask | 81.90 x 900 |
| Day's Range | 80.28 - 81.45 |
| 52 Week Range | 74.79 - 91.45 |
| Volume | 4,311,338 |
| Avg. Volume | 2,586,385 |
| Market Cap | 40.64B |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | 39.04 |
| EPS (TTM) | 2.07 |
| Earnings Date | Jul 28, 2021 - Aug 02, 2021 |
| Forward Dividend & Yield | 1.12 (1.28%) |
| Ex-Dividend Date | Jun 03, 2021 |
| 1y Target Est | 94.00 |
- Business Wire
Baxter to Host Second-Quarter 2021 Financial Results Conference Call for Investors
DEERFIELD, Ill., Jun 15, 2021--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its second-quarter 2021 financial results on Thursday, July 29, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/8371319 to pre-register for the call and receive the call information.
- Zacks
Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive
Baxter's (BAX) Theranova-enabled HDx therapy is likely to boost clinical outcomes and lower healthcare resource utilization.
- Business Wire
Baxter Presents Data at 58th ERA-EDTA Congress Indicating Theranova May Reduce Cardiovascular Events and Hospitalizations
Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today new data showing expanded hemodialysis (HDx) therapy enabled by the Theranova dialyzer may reduce cardiovascular events by 35% and hospitalization rates by 18% according to a new, large, multicenter, retrospective study of Colombian dialysis patients treated with long-term HDx compared to propensity-matched patients treated with High-Flux Hemodialysis.1 The study "Effectiveness of medium cut-off versus high f
